KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EBT: 2009-2024

Historic EBT for Charles River Laboratories International (CRL) over the last 16 years, with Dec 2024 value amounting to $93.1 million.

  • Charles River Laboratories International's EBT fell 4.43% to $87.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.2 million, marking a year-over-year decrease of 104.28%. This contributed to the annual value of $93.1 million for FY2024, which is 83.98% down from last year.
  • As of FY2024, Charles River Laboratories International's EBT stood at $93.1 million, which was down 83.98% from $581.3 million recorded in FY2023.
  • Charles River Laboratories International's 5-year EBT high stood at $623.0 million for FY2022, and its period low was $93.1 million during FY2024.
  • Over the past 3 years, Charles River Laboratories International's median EBT value was $581.3 million (recorded in 2023), while the average stood at $432.5 million.
  • As far as peak fluctuations go, Charles River Laboratories International's EBT skyrocketed by 47.04% in 2020, and later tumbled by 83.98% in 2024.
  • Over the past 5 years, Charles River Laboratories International's EBT (Yearly) stood at $447.1 million in 2020, then climbed by 7.51% to $480.7 million in 2021, then rose by 29.60% to $623.0 million in 2022, then decreased by 6.69% to $581.3 million in 2023, then slumped by 83.98% to $93.1 million in 2024.